{"id":"W2914616519","doi":"10.1016/j.ophtha.2019.01.013","title":"Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease","year":2019,"lang":"en","type":"article","venue":"Ophthalmology","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; Novartis (Canada); McGill University; University of Calgary; University of Alberta; University of Toronto; Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent; Sunnybrook Health Science Centre","funders":"Bayer Canada; Allergan; Novartis Pharmaceuticals Canada; Novartis; Roche; Bayer","keywords":"Medicine; Ranibizumab; Macular degeneration; Visual acuity; Choroidal neovascularization; Regimen; Dosing; Ophthalmology; Randomized controlled trial; Confidence interval; Diabetic retinopathy; Bevacizumab; Surgery; Internal medicine; Chemotherapy; Diabetes mellitus","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001080645,0.0007961615,0.001582273,0.0001747655,0.000615178,0.0005308449,0.000488032,0.0005509148,0.003066121],"category_scores_gemma":[0.001204889,0.0002335717,0.0008571159,0.0003078017,0.0004351253,0.0004185097,0.0002296564,0.001176227,0.0002472187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001615996,"about_ca_system_score_gemma":0.002677039,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04353398,"about_ca_topic_score_gemma":0.1709244,"domain_scores_codex":[0.9993809,0.0002119007,0.00002867126,0.00008911295,0.000179132,0.0001100998],"domain_scores_gemma":[0.999447,0.00007659548,0.0001654508,0.00003726264,0.00006098854,0.0002125447],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9026034,0.004936714,0.01832015,0.0007333212,0.002833971,0.0001267612,0.00009318946,0.0006213713,0.003616732,0.0003979841,0.007127414,0.058589],"study_design_scores_gemma":[0.7900283,0.05119069,0.1384269,0.0001529463,0.003417387,0.0003038709,0.0001022874,0.001598445,0.0009827687,0.0003694881,0.01334783,0.00007906734],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.977629,0.01100833,0.0002269074,0.001131742,0.000224556,0.0009623546,0.00182179,0.00004893459,0.00694638],"genre_scores_gemma":[0.988436,0.003342477,0.0007470852,0.001055734,0.0003660201,0.0006711361,0.002231182,0.000008108191,0.003142285],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.956466,"threshold_uncertainty_score":0.08656114,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004252280861809472,"score_gpt":0.2261937874485722,"score_spread":0.2219415065867627,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}